Crinetics Pharmaceuticals/$CRNX
1D1W1MYTD1Y5YMAX
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals Inc is a commercial-stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. Its main product, Palsonify (paltusotine), is a once-daily, oral treatment approved by the FDA for adults with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option. Additionally, the company's development pipeline includes several programs, including a late-stage investigational candidate, atumelnant, currently in development for CAH and ADCS, and CRN09682, a NDC candidate that is being developed to treat SST2-expressing NETs and other SST2-expressing solid tumors.
- Ticker
- $CRNX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 594
- Headquarters
- San Diego, United States
- Website
- www.crinetics.com
CRNX Metrics
BasicAdvanced
$9B
-
-$5.03
0.09
-
Price and volume
Market cap
$9B
Beta
0.09
52-week high
$84.71
52-week low
$28.73
Average daily volume
6.6M
Financial strength
Current ratio
15.571
Quick ratio
15.238
Long term debt to equity
3.407
Total debt to equity
3.959
Profitability
EBITDA (TTM)
-544.85
Gross margin (TTM)
-794.01%
Net profit margin (TTM)
-1,189.88%
Operating margin (TTM)
-1,302.52%
Effective tax rate (TTM)
-0.04%
Revenue per employee (TTM)
$70,000
Management effectiveness
Return on assets (TTM)
-26.28%
Return on equity (TTM)
-42.45%
Valuation
Price to revenue (TTM)
199.803
Price to book
7.5
Price to tangible book (TTM)
7.5
Price to free cash flow (TTM)
-19.81
Free cash flow yield (TTM)
-5.05%
Free cash flow per share (TTM)
-4.262
Growth
Revenue change (TTM)
2,928.45%
Earnings per share change (TTM)
21.91%
3-year revenue growth (CAGR)
105.83%
3-year earnings per share growth (CAGR)
13.85%
What the Analysts think about CRNX
Analyst ratings (Buy, Hold, Sell) for Crinetics Pharmaceuticals stock.
CRNX Financial Performance
Revenues and expenses
CRNX Earnings Performance
Company profitability
CRNX News
AllArticlesVideos
Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse
MarketBeat1 month ago
Crinetics Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Crinetics Pharmaceuticals, Inc. - CRNX
Business Wire1 month ago
Vertex's Crinetics Deal Balances Growth with Integration Risk
MarketBeat1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.